Horizon drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.
Built upon more than a decade of experience in the engineering of cell lines, our tools and services enable scientists to gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.
World leader in gene editing and gene modulation technologies.
Driving next wave of precision medicine.
Our ability to design and engineer a cell’s DNA to mimic a patient’s DNA creates valuable insights into the genetic drivers of disease, its diagnosis and ultimately treatment.
Enabling the global life science community.
Unique commercial team provides global market access.
In compliance with AIM rule 26, this section of Horizon’s website contains important information for investors including business description, details of Directors and advisors, news for investors, and share information. Horizon Discovery Group plc is incorporated in England with its main country of operation being the United Kingdom and additional headquarters in the United States of America and is listed on the London Stock Exchange’s AIM market under the ticker HZD. Horizon Discovery Group plc is subject to the UK City Code on Takeovers and Mergers. Horizon Discovery Group plc’s shares are currently only traded on AIM. There are currently no restrictions on the transfer of securities.